Phuturdex › Drugs › Benzylpenicillin
Drugs in development · updated 9 November 2026
Benzylpenicillin: clinical trials and development status
Other names and codes: Penicillin G
As of 9 November 2026 Benzylpenicillin is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 9 diseases. The most advanced phase is III.
Summary updated every week · data as of 9 November 2026. In Phuturdex you can follow Benzylpenicillin and get an email at every change or safety alert.
Sign in free →Approved uses in the United States (FDA)
Therapy Penicillin G Potassium Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. […]
Official documents
Use, doses, side effects and interactions: only these official documents are authoritative.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Infection | III | 1 | NCT07575009 |
| Neurosyphilis | III | 1 | NCT07904533 |
| Osteomyelitis | III | 1 | NCT07575009 |
| Sepsis | III | 1 | NCT07575009 |
| Treponemal Infections | III | 1 | NCT06877351 |
| Anaphylaxis | II | 1 | NCT06406114 |
| Drug Hypersensitivity | II | 1 | NCT06406114 |
| Hypersensitivity | II | 1 | NCT06406114 |
| Bacterial vaginosis | I | 1 | NCT06616168 |
Everything on Benzylpenicillin
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.